Insider trade

Vertex Pharmaceuticals (VRTX)Officer sold ~$364K

Joy Liu, Officer at Vertex Pharmaceuticals, sold ~$364K of Vertex Pharmaceuticals shares.

~$364K
Approx. value · 828 sh @ $439.91: 20K
Holds after · shares reported

Traded: Jun 1, 2026
Filed: Jun 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Mar 27, 2026CongressDisclosed purchase of VRTX — reported range $1,001 - $15,000
Apr 1, 2026InsiderOfficer sold ~$439K of VRTX shares in the open market
Apr 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”).”
Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
May 1, 2026InsiderOfficer sold ~$469K of VRTX shares in the open market
May 4, 2026Company filing · Form 8-K · ResultsReported its results
May 4, 2026InsiderDirector sold ~$135K of VRTX shares in the open market
May 12, 2026Insider · Their largest sale since 2023Officer sold ~$3.14M of VRTX shares in the open market
May 13, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval.”
May 14, 20265% stakeCapital Research Global Investors reported a passive stake (13G) of 8.3%
May 14, 20265% stakeCapital World Investors reported a passive stake (13G) of 10.1%
May 15, 2026Insider · 2 peopleInsiders: 2 sales (~$629K)
May 29, 2026InsiderOfficer sold ~$888K of VRTX shares in the open market
Jun 1, 2026 · this disclosureInsiderOfficer sold ~$364K of VRTX shares in the open market

What came next

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vertex Pharmaceuticals

For Vertex Pharmaceuticals, OQRO holds 2 Congress trade reports and 42 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.

Other recent filings by Joy Liu, EVP and Chief Legal Officer

The full history of Joy Liu, EVP and Chief Legal Officer is on the profile page.

How this filing works

Other disclosures at Vertex Pharmaceuticals

Everything OQRO holds on this company is on its VRTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data